198 chapter 2 Table 44. Baseline characteristics of included studies investigating immunocytochemistry reference country study design ntot ni included indeterminate cytology inclusion and exclusion criteria Khurana 2003 USA RS 57 19 atypical, carcinoma cannot be excluded TN; availability of adequate cell blocks; histologic f/u available Pisani 2003 Italy ? 25 25 Hürthle cell neoplasm cold TN on scintigraphy Collet 2005 France PS 114 34 indeterminate TN; histologic f/u available Mills 2005 UK PS 51 13 Thy3 TN; informed consent or part of inhouse laboratory audit Rossi 2005 Italy n.s. 99 37 follicular proliferation TN; sufficient material in both smear types; histologic f/u available Saggiorato 2005 Italy RS 125 125 follicular neoplasm TN; histologic f/u available Chandan 2006 USA RS 50 14 atypical, carcinoma cannot be excluded TN; adequate cell blocks and histologic f/u available Sapio 2007 (1) Italy RS 144 47 microfollicular pattern with or without Hürthle cells, scant colloid, no nuclear atypia TN; histological f/u available Aiad 2008 Egypt PS 28 17 indeterminate TN; histologic f/u available Bartolazzi 2008 Italy PS 465 465 Thy3 TN; histologic f/u available Pennelli 2009 Italy PS 100 100 follicular neoplasm TN; adequate smears and cell blocks available; histologic f/u available; no previous thyroid surgery Troncone 2009 Italy RS 51 51 suspicious for Hürthle cell neoplasm cell blocks and histologic f/u available Asioli 2010 Italy RS 78 53 Thy3 sufficient cell blocks available; clinical or radiological, and histologic f/u available Raggio 2010 Italy RS 100 60 follicular lesion TN; histologic f/u available Cochand-Priollet 2011 France PS 150 51 Bethesda III or IV liquid based cytology, histologic f/u available Fadda 2011 Italy RS 120 50 Thy3 histologic f/u available Lacoste-Collin 2014 France PS 123 37 Bethesda IV histologic f/u available Addati 2015 Italy RS 127 68 Bethesda III or IV HBME-1 ICC carried out on archived slides; histologic f/u available Zhang 2015 USA RS 51 51 Bethesda III or IV ≥100 lesional follicular cells on a single cytology slide; compatible histologic f/u available TOTAL 2,058 1,317 CK-19: cytokeratin-19. FTC: follicular thyroid carcinoma. f/u: follow-up. FTC-OV: FTC, oncocytic variant (Hürthle cell carcinoma). FVPTC: papillary thyroid carcinoma, follicular variant. Gal-3: galectin-3. GLUT-1: Glucose Transporter-1. HBME-1: Hector Battifora mesothelial antigen-1. i: applies to indeterminate thyroid nodules only. ICC: immunocytochemistry. Ki-67: Ki-67 protein. KS: keratan sulphate. MTC: medullary thyroid carcinoma. ni: total number of indeterminate thyroid nodules included in our analysis. n.s.: not specified. ntot: total number of thyroid nodules in study. p27: p27 cyclin-dependent kinase inhibitor. PS: prospective. PTC: papillary thyroid carcinoma. RET: RET proto-oncogene. RS: retrospective. TN: thyroid nodule. TPO: thyroperoxidase. TROP-2: human trophoblast cell surface marker. y: years.
RkJQdWJsaXNoZXIy MTk4NDMw